亿帆医药
(002019)
| 流通市值：101.31亿 | | | 总市值：146.45亿 |
| 流通股本：8.41亿 | | | 总股本：12.16亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,858,211,534.78 | 2,632,089,783.35 | 1,325,969,392.93 | 4,068,107,333.94 |
| 营业收入 | 3,858,211,534.78 | 2,632,089,783.35 | 1,325,969,392.93 | 4,068,107,333.94 |
| 二、营业总成本 | 3,531,892,029.96 | 2,363,162,281.95 | 1,189,455,724.43 | 4,041,933,714.51 |
| 营业成本 | 2,019,896,584.59 | 1,374,809,781.73 | 697,906,895.23 | 2,121,932,748.61 |
| 税金及附加 | 37,868,104.71 | 29,528,550.8 | 10,025,427.34 | 45,949,999.29 |
| 销售费用 | 962,031,504.27 | 638,226,395.9 | 314,782,530.39 | 1,119,147,520.07 |
| 管理费用 | 279,807,921.91 | 173,744,849.65 | 89,535,119.03 | 383,691,613.8 |
| 研发费用 | 182,438,180.13 | 114,594,982.81 | 59,876,908.4 | 312,383,570.82 |
| 财务费用 | 49,849,734.35 | 32,257,721.06 | 17,328,844.04 | 58,828,261.92 |
| 其中:利息费用 | 52,655,529.37 | 33,443,730.44 | 16,667,241.75 | 75,552,151.11 |
| 其中:利息收入 | 7,047,405.26 | 4,334,459.37 | 2,317,719.1 | 13,129,460.86 |
| 加:公允价值变动收益 | - | - | - | 10,256.5 |
| 加:投资收益 | -6,930,848.09 | -1,288,863.23 | -4,560,572.47 | -15,069,239.18 |
| 资产处置收益 | 34,217,935.54 | 2,198,867.23 | 2,282,436.45 | 2,570,803.44 |
| 资产减值损失(新) | -20,693,476.75 | -10,823,614.64 | -4,285,452.76 | -887,364,040.01 |
| 信用减值损失(新) | -50,850,079.08 | -50,826,479.16 | -16,262,223.14 | -64,424,928.05 |
| 其他收益 | 101,570,508.05 | 83,284,962.09 | 45,164,802.43 | 55,391,348.6 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 383,633,544.49 | 291,472,373.69 | 158,852,659.01 | -882,712,179.27 |
| 加:营业外收入 | 3,460,039.53 | 2,854,677.57 | 184,120.98 | 18,550,050.5 |
| 减:营业外支出 | 2,036,783.86 | 676,406.7 | 122,948.13 | 4,868,578.14 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 385,056,800.16 | 293,650,644.56 | 158,913,831.86 | -869,030,706.91 |
| 减:所得税费用 | 77,296,802.65 | 81,204,665.33 | 41,365,369.65 | 16,618,640.14 |
| 六、净利润 | 307,759,997.51 | 212,445,979.23 | 117,548,462.21 | -885,649,347.05 |
| 持续经营净利润 | 307,759,997.51 | 212,445,979.23 | 117,548,462.21 | -885,649,347.05 |
| 归属于母公司股东的净利润 | 366,380,130.89 | 253,226,615.6 | 146,099,164.96 | -551,073,063.61 |
| 少数股东损益 | -58,620,133.38 | -40,780,636.37 | -28,550,702.75 | -334,576,283.44 |
| (一)基本每股收益 | 0.3 | 0.21 | 0.12 | -0.45 |
| (二)稀释每股收益 | 0.3 | 0.21 | 0.12 | -0.45 |
| 八、其他综合收益 | -10,825,241.37 | -17,359,424.85 | -13,919,671.49 | 51,238,166.35 |
| 归属于母公司股东的其他综合收益 | -10,798,610.7 | -17,384,862.25 | -13,912,833.38 | 50,967,750.41 |
| 九、综合收益总额 | 296,934,756.14 | 195,086,554.38 | 103,628,790.72 | -834,411,180.7 |
| 归属于母公司股东的综合收益总额 | 355,581,520.19 | 235,841,753.35 | 132,186,331.58 | -500,105,313.2 |
| 归属于少数股东的综合收益总额 | -58,646,764.05 | -40,755,198.97 | -28,557,540.86 | -334,305,867.5 |
| 公告日期 | 2024-10-31 | 2024-08-15 | 2024-04-24 | 2024-04-20 |
| 审计意见(境内) | | | | 标准无保留意见 |